Point72 Asset Management
ITOS

Point72 Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Point72 Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-921
Closed -$10.1K – 2460
2023
Q3 		$10.1K Buy
+921
New +$11.8K ﹤0.01% 2335
2023
Q2 		– Sell
-3,620
Closed -$49.3K – 2466
2023
Q1 		$49.3K Buy
+3,620
New +$64.9K ﹤0.01% 1785
2022
Q1 		– Sell
-105,030
Closed -$4.89M – 1277
2021
Q4 		$4.89M Buy
+105,030
New +$3.5M 0.02% 680

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management's ITOS Position: Q4 2023 in Review

Point72 Asset Management sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 921 shares — an estimated $10.1K sold.

Point72 Asset Management first reported a position in ITOS in Q4 2021 and held it in 3 quarters. The position peaked at $4.89M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Point72 Asset Management reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 921 iTeos Therapeutics shares in Q4 2023, an estimated $10.1K.
  • Point72 Asset Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 3 quarters.
  • Point72 Asset Management's iTeos Therapeutics position peaked at $4.89M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.